S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
2 Important Retail Stock Battles to Watch
27 U.S. Cities Where Stocks Yield 26% a Year (Ad)pixel
Sinema took Wall Street money while killing tax on investors
MarketBeat: Week in Review 8/8 - 8/12
Expanded IRS free-file system one step closer in Dems' bill
How Much Longer Will It Be Under $1? (Ad)pixel
Climate bill: Could coal communities shift to nuclear?
Germans urged to cap heat in offices this winter to save gas
Italy's Lake Garda shrinks to near-historic low amid drought
How Much Longer Will It Be Under $1? (Ad)pixel
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
2 Important Retail Stock Battles to Watch
27 U.S. Cities Where Stocks Yield 26% a Year (Ad)pixel
Sinema took Wall Street money while killing tax on investors
MarketBeat: Week in Review 8/8 - 8/12
Expanded IRS free-file system one step closer in Dems' bill
How Much Longer Will It Be Under $1? (Ad)pixel
Climate bill: Could coal communities shift to nuclear?
Germans urged to cap heat in offices this winter to save gas
Italy's Lake Garda shrinks to near-historic low amid drought
How Much Longer Will It Be Under $1? (Ad)pixel
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
2 Important Retail Stock Battles to Watch
27 U.S. Cities Where Stocks Yield 26% a Year (Ad)pixel
Sinema took Wall Street money while killing tax on investors
MarketBeat: Week in Review 8/8 - 8/12
Expanded IRS free-file system one step closer in Dems' bill
How Much Longer Will It Be Under $1? (Ad)pixel
Climate bill: Could coal communities shift to nuclear?
Germans urged to cap heat in offices this winter to save gas
Italy's Lake Garda shrinks to near-historic low amid drought
How Much Longer Will It Be Under $1? (Ad)pixel
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
2 Important Retail Stock Battles to Watch
27 U.S. Cities Where Stocks Yield 26% a Year (Ad)pixel
Sinema took Wall Street money while killing tax on investors
MarketBeat: Week in Review 8/8 - 8/12
Expanded IRS free-file system one step closer in Dems' bill
How Much Longer Will It Be Under $1? (Ad)pixel
Climate bill: Could coal communities shift to nuclear?
Germans urged to cap heat in offices this winter to save gas
Italy's Lake Garda shrinks to near-historic low amid drought
How Much Longer Will It Be Under $1? (Ad)pixel
NASDAQ:STRO

Sutro Biopharma - STRO Stock Forecast, Price & News

$7.09
+0.29 (+4.26%)
(As of 08/12/2022 12:00 AM ET)
Add
Compare
Today's Range
$6.81
$7.18
50-Day Range
$3.41
$7.09
52-Week Range
$3.33
$23.70
Volume
315,458 shs
Average Volume
483,246 shs
Market Capitalization
$369.81 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$24.33

Sutro Biopharma MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
243.2% Upside
$24.33 Price Target
Short Interest
Bearish
12.05% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.70
Upright™ Environmental Score
News Sentiment
0.20mentions of Sutro Biopharma in the last 14 days
Based on 17 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($2.36) to ($2.91) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.06 out of 5 stars

Medical Sector

692nd out of 1,117 stocks

Biological Products, Except Diagnostic Industry

106th out of 175 stocks

STRO stock logo

About Sutro Biopharma (NASDAQ:STRO) Stock

Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF+.The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma that is in Phase 1 clinical trials; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers, which is in Phase 1 clinical trials. It has collaboration and license agreements with Merck Collaboration to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; and Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.

Sutro Biopharma Stock Performance

NASDAQ:STRO opened at $7.09 on Friday. The stock has a market capitalization of $332.76 million, a PE ratio of -2.45 and a beta of 0.94. The business has a 50 day simple moving average of $5.32 and a two-hundred day simple moving average of $6.76. The company has a debt-to-equity ratio of 0.05, a current ratio of 7.44 and a quick ratio of 5.90. Sutro Biopharma has a 1-year low of $3.33 and a 1-year high of $23.70.

Sutro Biopharma (NASDAQ:STRO - Get Rating) last announced its earnings results on Monday, August 8th. The company reported ($0.55) EPS for the quarter, missing analysts' consensus estimates of ($0.46) by ($0.09). Sutro Biopharma had a negative return on equity of 55.57% and a negative net margin of 252.33%. On average, research analysts predict that Sutro Biopharma will post -3.1 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on the company. JMP Securities reaffirmed a "buy" rating and issued a $20.00 price objective on shares of Sutro Biopharma in a research note on Wednesday, July 6th. Wedbush cut their target price on Sutro Biopharma from $30.00 to $20.00 in a research report on Tuesday, May 10th. Piper Sandler increased their target price on Sutro Biopharma to $16.00 in a research report on Monday, July 4th. Finally, HC Wainwright cut their target price on Sutro Biopharma from $35.00 to $30.00 in a research report on Wednesday, May 11th.

Receive STRO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sutro Biopharma and its competitors with MarketBeat's FREE daily newsletter.

STRO Stock News Headlines

Short Volatility Alert: Sutro Biopharma, Inc.
See More Headlines
Receive STRO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sutro Biopharma and its competitors with MarketBeat's FREE daily newsletter.

STRO Company Calendar

Last Earnings
8/08/2022
Today
8/13/2022
Next Earnings (Estimated)
11/09/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:STRO
Fax
N/A
Employees
224
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$24.33
High Stock Price Forecast
$30.00
Low Stock Price Forecast
$16.00
Forecasted Upside/Downside
+243.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-105,540,000.00
Net Margins
-252.33%
Pretax Margin
-247.63%

Debt

Sales & Book Value

Annual Sales
$61.88 million
Book Value
$4.01 per share

Miscellaneous

Free Float
49,501,000
Market Cap
$369.81 million
Optionable
Not Optionable
Beta
0.94

Key Executives

  • Mr. William J. Newell J.D. (Age 64)
    CEO & Director
    Comp: $1.06M
  • Mr. Edward C. Albini (Age 64)
    CFO & Sec.
    Comp: $596.4k
  • Dr. Trevor J. Hallam (Age 63)
    Pres of Research & Chief Scientific Officer
    Comp: $882.83k
  • Dr. Arturo M. Molina FACP (Age 63)
    M.D., M.S., MS, Chief Medical Officer
    Comp: $691.83k
  • Ms. Jane Chung R.Ph. (Age 51)
    Chief Commercial Officer
    Comp: $832.52k
  • Dr. James R. Swartz Ph.D.
    Sc.D., Founder
  • Dr. Shabbir T. Anik (Age 69)
    Chief Technical Operations Officer
  • Ms. Annie J. Chang M.B.A.
    VP of Investor Relations
  • Mr. David Pauling J.D.
    M.A., Gen. Counsel
  • Ms. Linda A. Fitzpatrick (Age 65)
    Chief People & Communications Officer













STRO Stock - Frequently Asked Questions

Should I buy or sell Sutro Biopharma stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Sutro Biopharma in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" STRO shares.
View STRO analyst ratings
or view top-rated stocks.

What is Sutro Biopharma's stock price forecast for 2022?

4 brokers have issued 12-month price targets for Sutro Biopharma's stock. Their STRO share price forecasts range from $16.00 to $30.00. On average, they expect the company's share price to reach $24.33 in the next year. This suggests a possible upside of 243.2% from the stock's current price.
View analysts price targets for STRO
or view top-rated stocks among Wall Street analysts.

How have STRO shares performed in 2022?

Sutro Biopharma's stock was trading at $14.88 on January 1st, 2022. Since then, STRO stock has decreased by 52.4% and is now trading at $7.09.
View the best growth stocks for 2022 here
.

When is Sutro Biopharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 9th 2022.
View our STRO earnings forecast
.

How were Sutro Biopharma's earnings last quarter?

Sutro Biopharma, Inc. (NASDAQ:STRO) issued its quarterly earnings results on Monday, August, 8th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.46) by $0.09. Sutro Biopharma had a negative net margin of 252.33% and a negative trailing twelve-month return on equity of 55.57%.

What is William J. Newell's approval rating as Sutro Biopharma's CEO?

11 employees have rated Sutro Biopharma Chief Executive Officer William J. Newell on Glassdoor.com. William J. Newell has an approval rating of 100% among the company's employees. This puts William J. Newell in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Sutro Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sutro Biopharma investors own include Pfizer (PFE), VBI Vaccines (VBIV), Aldeyra Therapeutics (ALDX), Dynavax Technologies (DVAX), Fulcrum Therapeutics (FULC), IDEAYA Biosciences (IDYA), Provention Bio (PRVB), Sorrento Therapeutics (SRNE), Xeris Biopharma (XERS) and AbbVie (ABBV).

When did Sutro Biopharma IPO?

(STRO) raised $75 million in an initial public offering (IPO) on Thursday, September 27th 2018. The company issued 5,000,000 shares at $14.00-$16.00 per share. Cowen and Piper Jaffray served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

What is Sutro Biopharma's stock symbol?

Sutro Biopharma trades on the NASDAQ under the ticker symbol "STRO."

Who are Sutro Biopharma's major shareholders?

Sutro Biopharma's stock is owned by many different institutional and retail investors. Top institutional investors include Franklin Resources Inc. (8.04%), Baillie Gifford & Co. (3.97%), FMR LLC (1.27%), Northern Trust Corp (0.80%), Walleye Capital LLC (0.58%) and JPMorgan Chase & Co. (0.33%). Insiders that own company stock include Arturo Md Molina, John Gordon Freund, Nicki Vasquez, Trevor Hallam and William J Newell.
View institutional ownership trends
.

How do I buy shares of Sutro Biopharma?

Shares of STRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Sutro Biopharma's stock price today?

One share of STRO stock can currently be purchased for approximately $7.09.

How much money does Sutro Biopharma make?

Sutro Biopharma (NASDAQ:STRO) has a market capitalization of $369.81 million and generates $61.88 million in revenue each year. The company earns $-105,540,000.00 in net income (profit) each year or ($2.89) on an earnings per share basis.

How many employees does Sutro Biopharma have?

The company employs 224 workers across the globe.

How can I contact Sutro Biopharma?

Sutro Biopharma's mailing address is 310 Utah Avenue Suite 150, South San Francisco CA, 94080. The official website for the company is www.sutrobio.com. The company can be reached via phone at (650) 392-8412 or via email at ajchang@sutrobio.com.

This page (NASDAQ:STRO) was last updated on 8/13/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.